Publish with Us Search
Publish with Us

GenoMed Connect

ISSN: 3105-3645
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Special Issues

Antibody-Based Therapeutics and Diagnostics in Precision Genomic Medicine

A special issue of GenoMed Connect (3105-3645)

Submission Deadline: December 31, 2025 Published Articles: 0 Submit your Article Share

Special Issue Editors

Yuanzhi Chen

Lead Guest Editor

Lijie Yuan

Co-Guest Editor

Special Issue Information

This Special Issue aims to highlight recent advances and future directions in the development and application of antibody-based technologies in precision medicine, translational genomics, and clinical practice. Antibodies—including monoclonal antibodies, bispecific antibodies, nanobodies, and antibody-drug conjugates (ADCs)—are increasingly being integrated into genomic medicine workflows to enable disease-specific diagnosis, targeted therapy, and molecular imaging.

We invite contributions from multidisciplinary teams that explore how antibody engineering, sequencing-based discovery platforms, and genomic data can be jointly leveraged to accelerate the development of personalized interventions in cancer, infectious diseases, rare genetic disorders, autoimmune diseases, and more.

This Special Issue will bring together cutting-edge research and reviews on antibody-based strategies that reflect the convergence of immunotechnology and genomics, bridging basic science and clinical applications.

Topics of interest
  • Genomics-driven discovery of therapeutic antibodies and biomarkers
  • CRISPR/Cas system delivery via antibody formats
  • Antibody development platforms (e.g., phage/yeast/mammalian display, single B cell sequencing)
  • Integration of antibody profiling with omics data for patient stratification
  • Applications of monoclonal and bispecific antibodies in precision oncology
  • Microbial genomics and antibody-based neutralization strategies
  • Antibody-drug conjugates (ADCs) targeting genomically-defined tumor antigens
  • Bioinformatics and AI in antibody design and epitope prediction
  • Nanobody and scFv applications in diagnostics and targeted delivery
  • Regulatory and ethical issues in antibody-based personalized therapies
Target Audience

This Special Issue will benefit from a strong professional network across the fields of antibody engineering, genomic medicine, and translational research.

Benefits of submitting by the deadline
  • No article processing charges
  • Complimentary language editing

For further details, please contact the editorial office at: info@scifiniti.com

Share
Help